Drug intelligence / Profile preview

Investigational varicella vaccine

Development stage: Phase 3
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

The Investigational varicella vaccine, also known as VNS Vaccine, is a biological vaccine developed by GlaxoSmithKline. It is currently undergoing Phase 3a clinical trials to assess its immunogenicity and safety. The vaccine is intended to prevent varicella (chickenpox) in healthy children aged 12 to 15 months, administered as both a first and second dose, and is being compared against the approved Varivax vaccine.

Beyond the preview

Go deeper on Investigational varicella vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Investigational varicella vaccine.

Explore the full profile